Effects of atriopeptin III on isolated rat afferent and efferent arterioles.

Effects of atriopeptin III on isolated rat afferent and efferent arterioles.
复制标题

atriopeptin III 对离体大鼠传入和传出小动脉的影响。

DOI:
10.1152/ajprenal.1991.261.6.f1102
复制
发表时间:
1991
期刊:
The American journal of physiology
影响因子:
--
通讯作者:
Conger,JD
Conger,JD
中科院分区:
--
文献类型:
--
作者:
Lanese,DM;Yuan,BH;Falk,SA;Conger,JD

文献摘要

被引文献

相似文献

在一个可测量管腔直径的系统中,观察了心房肽Ⅲ(AP Ⅲ)对离体制备的大鼠肾传入(AA)和传出(EA)小动脉的作用。AP III(10(-13)-10(-7)M)对未预收缩的AA管腔直径无影响。然而,当用血管紧张素II(ANG II)或去甲肾上腺素(NE)预收缩AA时,AP III以浓度依赖性方式增加管腔直径至预收缩基线值。最大血管舒张发生在10(-10)M AP III。与AA不同,50%至10(-10)M AP III对EA的收缩作用进一步抑制了ANG II或NE预处理的EA。ANG II预收缩AA到AP III的扩张不受吲哚美辛的抑制。收缩的EA AP III没有改变[Sar 1-Ala 8] ANG II,依那普利,OKY 046,或酚妥拉明。结果表明,在孤立的肾小动脉AP III扩张preconstricted AA,但收缩EA,要么没有预处理或已preconstricted与其他激动剂。AP III对预收缩AA的作用不需要血管扩张剂前列腺素介导。AP III对EA的收缩作用不依赖于血管紧张素、血栓素或α-肾上腺素能介导。
The effects of atriopeptin III (AP III) on in vitro prepared afferent (AA) and efferent arterioles (EA) from rat kidneys were tested in a system in which lumen diameter could be measured. AP III (10(-13)-10(-7) M) had no effect on lumen diameter of AA that were not preconstricted. When AA were preconstricted with either angiotensin II (ANG II) or norepinephrine (NE), however, AP III increased lumen diameter in a concentration-dependent manner to the preconstriction baseline value. Maximal vasodilation occurred at 10(-10) M AP III. Unlike AA, EA constricted by 50% to 10(-10) M AP III further constricted EA that were pretreated with ANG II or NE. Dilation in ANG II-preconstricted AA to AP III was not inhibited by indomethacin. Constriction of EA to AP III was not altered by [Sar1-Ala8] ANG II, enalapril, OKY 046, or phentolamine. Results indicate that in isolated renal arterioles AP III dilates preconstricted AA but constricts EA that have either not been pretreated or have been preconstricted with other agonists. The effect of AP III on preconstricted AA does not require vasodilator prostaglandin mediation. The constrictor effect of AP III on EA is not dependent on angiotensin, thromboxane, or alpha-adrenergic mediation.